Impact of age on clinical outcomes and response to serelaxin in patients with acute heart failure: An analysis from the RELAX‐AHF‐2 trial

Abstract

AbstractAimsAcute heart failure (AHF) is a major cause of hospitalizations and death in the elderly. However, elderly patients are often underrepresented in randomized clinical trials. We analysed the impact of age on clinical outcomes and response to treatment in patients enrolled in Relaxin in Acute Heart Failure (RELAX‐AHF‐2), a study that included older patients than in previous AHF trials.Methods and resultsThe RELAX‐AHF‐2 randomized patients admitted for AHF to infusion of serelaxin or placebo. We examined the association of pre‐specified clinical outcomes and treatment effect according to age categories [(years): <65 (n = 1411), 65–74 (n = 1832), 75–79 (n = 1222), 80–84 (n = 1156) and ≥85 (n = 924)]. The mean age of the 6545 patients enrolled in RELAX‐AHF‐2 was 73.0 ± 11 years. The risk of all‐cause and cardiovascular (CV) death (all p < 0.001) as well as the composite endpoint of CV death or heart failure/renal failure rehospitalization through 180 days (p = 0.002) and hospital discharge through day 60 (p = 0.013) were all directly associated with age categories. Age remained independently associated with outcomes after adjustment for clinical confounders and the results were consistent when age was analysed continuously. No clinically significant change in treatment effects of serelaxin was observed across age categories for the pre‐specified endpoints (interaction p > 0.05).ConclusionElderly patients are at higher risk of short‐ and long‐term CV outcomes after a hospitalization for AHF. Further efforts are needed to improve CV outcomes in this population.